Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 16:2024:3163839.
doi: 10.1155/2024/3163839. eCollection 2024.

Molecular Signature of miR-34a/NEAT-1/p53 Axis in Mycosis Fungoides

Reham Fares  1 , Shimaa M Elasmer  2 , Abeer Khalefa A  3 , Olfat G Shaker  4 , Samar M El-Tahlawi  5 , Ahmed Sabri  6 , Sara M Yaseen  7
Affiliations

Molecular Signature of miR-34a/NEAT-1/p53 Axis in Mycosis Fungoides

Reham Fares et al. Dermatol Res Pract. .

Abstract

Background: Mycosis fungoides (MF) is a type of cutaneous T-cell lymphoma where red rash exists on the skin. Understanding the role of miRNAs and ncRNAs in p53-response has become an open discussion, as they can regulate p53 or its downstream targets, and ncRNAs themselves.

Objectives: To evaluate the serum levels of NEAT-1, miR-34a, and p53 in MF patients and its relation to healthy controls to indicate whether it has a potential role in the pathogenesis of the disease. Subjects and Methods. This prospective case-control study was carried out on 75 subjects subdivided into two groups, 35 MF patients (stages 1 and II) and 40 matched healthy controls. Their clinical investigations and serum biomarkers (NEAT-1, miR-34a, and p53) were measured.

Results: There were significant elevations in the expression levels of both NEAT-1 (5.10 ± 1.16) and p53 (277.28 ± 62.02) in the serum of MF patients in comparison with controls (1.01 ± 0.031) and (194.29 ± 16.039), respectively, while the level of miR-34a tends to decrease in MF patients (0.24 ± 0.15). There are no significant difference between MF stages and the level of miR-34a, while in NEAT-1 and p53, there are significant differences with p value <0.05 between the stages and the biomarkers. There is a positive correlation between the %BSA and miR-34a and a slightly positive correlation between NEAT-1 and P53 with (r = 0.353, p=0.037) and (r = 0112, p=0.05), respectively. There were also negative correlations between disease duration and NEAT-1 with (r = -0.341, p=0.045) and between B2 microglobulin level and p53 (r = -0.373, p=0.027).

Conclusion: The combination of miR-34a, NEAT-1, and p53 may be considered as potential biomarkers that play an active role in the disease process of MF for helping in its early diagnosis and stage identification as well.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Comparison of concentration levels of serum biomarkers between MF patients' group and healthy controls: (a) miR-34a; (b) NEAT-1; (c) p53.
Figure 2
Figure 2
Relationship between the stages of MF and the serum biomarkers among the studied groups: (a) the expression level of miR-34a; (b) the expression level of NEAT-1; (c) the concentration level of p53.
Figure 3
Figure 3
Correlation between the serum biomarkers among MF patients: (a) miR-34a and %BSA; (b) NEAT-1 and p53; (c) NEAT-1 and disease duration; (d) B2 microglobulin level and p53.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Youssef R., Hegazy R. A., Fawzy M. M., et al. Peroxisome proliferator-activated receptor gamma, a possible culprit in mycosis fungoides: An immunohistochemical study. Journal of the European Academy of Dermatology and Venereology . 2012;26(12):1522–1532. doi: 10.1111/j.1468-3083.2011.04333.x. - DOI - PubMed
    1. Vora R., Mubashir S., Talavia P., Anjaneyan G. Mycosis fungoides: Tumour d’emblee. Indian dermatology online journal . 2012;3(2):122–124. doi: 10.4103/2229-5178.96709. - DOI - PMC - PubMed
    1. Finotti A., Fabbri E., Lampronti I., Gasparello J., Borgatti M., Gambari R. MicroRNAs and long non-coding RNAs in genetic diseases. Molecular Diagnosis and Therapy . 2019;23(2):155–171. doi: 10.1007/s40291-018-0380-6. - DOI - PMC - PubMed
    1. Ratti M., Lampis A., Ghidini M., et al. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: First steps from bench to bedside. Targeted Oncology . 2020;15(3):261–278. doi: 10.1007/s11523-020-00717-x. - DOI - PMC - PubMed
    1. Niderla-Bielińska J., Jankowska-Steifer E., Włodarski P. Non-coding RNAs and human diseases: Current status and future perspectives. International Journal of Molecular Sciences . 2023;24(14):p. 11679. doi: 10.3390/ijms241411679.11679 - DOI - PMC - PubMed

LinkOut - more resources